Absci's ABS-201 Shows Promising Early Safety Data in Hair Loss Trial
Event summary
- Phase 1 trial of ABS-201 shows favorable safety profile with no serious adverse events reported across four dose cohorts.
- Estimated half-life of at least 65 days suggests potential for infrequent dosing (two or three injections over six months).
- Multiple ascending dose portion initiated in androgenetic alopecia participants; interim proof-of-concept data expected in H2 2026.
- Phase 2 trial for endometriosis anticipated to begin later this year.
The big picture
Absci's ABS-201 represents a novel approach in targeting prolactin receptors for hair regrowth and endometriosis treatment. The positive interim safety data positions the company to compete in two high-need markets—hair loss, with limited FDA-approved treatments, and endometriosis, where current therapies often fall short. If successful, ABS-201 could redefine therapeutic options for millions of patients.
What we're watching
- Clinical Efficacy
- Whether interim proof-of-concept data in H2 2026 will validate ABS-201's potential for hair regrowth.
- Market Potential
- The pace at which Absci can position ABS-201 as a best-in-class treatment for both androgenetic alopecia and endometriosis.
- Regulatory Pathway
- How the Phase 2 trial for endometriosis progresses, given the condition's significant unmet medical need.
Related topics